These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
76 related articles for article (PubMed ID: 9864919)
1. Retrospective analysis of mantle cell lymphoma: experience of the "Gruppo Italiano per lo Studio dei Linfomi" (GISL). Callea V; Clò V; Morabito F; Baldini L; Stelitano C; Narni F; Avanzini P; Brugiatelli M; Silingardi V Haematologica; 1998 Nov; 83(11):993-7. PubMed ID: 9864919 [TBL] [Abstract][Full Text] [Related]
2. Validation of the international prognostic index in working formulation group A low-grade non-Hodgkin's lymphoma: retrospective analysis of 137 patients from the Gruppo Italiano per lo Studio dei Linfomi registry. Stelitano C; Baldini L; Pieresca C; Callea V; Angrilli F; Clò V; Partesotti G; Merli F; Cavanna L; Morabito F; Federico M; Brugiatelli M; Silingardi V Haematologica; 2000 Feb; 85(2):154-9. PubMed ID: 10681722 [TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics, treatment outcome and survival of 36 adult patients with primary anaplastic large cell lymphoma. Gruppo Italiano per lo Studio dei Linfomi (GISL). Longo G; Fiorani C; Sacchi S; Callea V; Lombardo M; Federico M; Stelitano C; Angrilli F; Vallisa D; Gobbi PG; Ilariucci F; Frassoldati A; Petrini M; Silingardi V Haematologica; 1999 May; 84(5):425-30. PubMed ID: 10329921 [TBL] [Abstract][Full Text] [Related]
4. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage]. Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383 [TBL] [Abstract][Full Text] [Related]
5. Weekly administration of vincristine, cyclophosphamide, mitoxantrone and bleomycin (VEMB) in the treatment of elderly aggressive non Hodgkin's lymphoma. Gruppo Italiano per lo Studio dei Linfomi. Merli F; Federico M; Avanzini P; Ilariucci F; Stelitano C; Iannitto E; Colombi M; Vallisa D; Santagati G; Picinini L Haematologica; 1998 Mar; 83(3):217-21. PubMed ID: 9573675 [TBL] [Abstract][Full Text] [Related]
6. Primary localized stages I and II non-Hodgkin's lymphoma of the nasopharynx: a retrospective 17-year single institutional experience. Mohammadianpanah M; Ahmadloo N; Mozaffari MA; Mosleh-Shirazi MA; Omidvari S; Mosalaei A Ann Hematol; 2009 May; 88(5):441-7. PubMed ID: 18931844 [TBL] [Abstract][Full Text] [Related]
7. Mantle cell lymphoma: a retrospective study on 27 patients. Clinical features and natural history. Bertini M; Rus C; Freilone R; Botto B; Calvi R; Novero D; Orsucci L; Vitolo U; Palestro G; Resegotti L Haematologica; 1998 Apr; 83(4):312-6. PubMed ID: 9592980 [TBL] [Abstract][Full Text] [Related]
8. The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study. Federico M; Luminari S; Gobbi PG; Sacchi S; Di Renzo N; Lombardo M; Merli F; Baldini L; Stelitano C; Partesotti G; Polimeno G; Montanini A; Mammi C; Brugiatelli M Eur J Haematol; 2006 Mar; 76(3):217-29. PubMed ID: 16451396 [TBL] [Abstract][Full Text] [Related]
9. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma. Rossi G; Donisi A; Casari S; Re A; Cadeo G; Carosi G Cancer; 1999 Dec; 86(11):2391-7. PubMed ID: 10590382 [TBL] [Abstract][Full Text] [Related]
10. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. Czuczman MS; Weaver R; Alkuzweny B; Berlfein J; Grillo-López AJ J Clin Oncol; 2004 Dec; 22(23):4711-6. PubMed ID: 15483015 [TBL] [Abstract][Full Text] [Related]
11. [CEOP regimen in the treatment for non-Hodgkin's lymphoma]. Huang HQ; Lin XB; Pan ZH; Bu Q; Gao Y; Wang BF; Cai QQ; Xia ZJ; Xu RH; Jiang WQ; Guan ZZ Zhonghua Zhong Liu Za Zhi; 2007 May; 29(5):391-5. PubMed ID: 17892140 [TBL] [Abstract][Full Text] [Related]
12. [Prognostic factors of primary non-Hodgkin's lymphoma of the nasal cavity--a report of 129 cases]. Yao B; Li YX; Fang H; Jin J; Liu XF; Yu ZH Ai Zheng; 2006 Apr; 25(4):465-70. PubMed ID: 16613682 [TBL] [Abstract][Full Text] [Related]
13. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma]. Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686 [TBL] [Abstract][Full Text] [Related]
14. [Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil]. Qin Y; Shi YK; He XH; Yang JL; Yang S; Yu YX; Li B; Wang QL; Zhou LQ; Sun Y Ai Zheng; 2006 Apr; 25(4):481-5. PubMed ID: 16613685 [TBL] [Abstract][Full Text] [Related]
15. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma]. Zhang HY; Lin TY; Jiang WQ; Zhang L; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560 [TBL] [Abstract][Full Text] [Related]
16. Treatment results of tonsillar lymphoma: a 10-year experience. Mohammadianpanah M; Omidvai S; Mosalei A; Ahmadloo N Ann Hematol; 2005 Apr; 84(4):223-6. PubMed ID: 15042316 [TBL] [Abstract][Full Text] [Related]
17. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. Simonelli C; Spina M; Cinelli R; Talamini R; Tedeschi R; Gloghini A; Vaccher E; Carbone A; Tirelli U J Clin Oncol; 2003 Nov; 21(21):3948-54. PubMed ID: 14581418 [TBL] [Abstract][Full Text] [Related]
18. [Primary non-Hodgkin's lymphoma of the nasal cavity at early stage: long-term treatment outcomes and prognostic analyses of 108 cases]. He YF; Zhang YJ; Li YH; Lin TY; Xia YF; Lu TX; Huang HQ; Jiang WQ; Xian CG; He YJ; Guan ZZ Ai Zheng; 2006 Dec; 25(12):1538-42. PubMed ID: 17166382 [TBL] [Abstract][Full Text] [Related]
19. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL). Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814 [TBL] [Abstract][Full Text] [Related]
20. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Escalón MP; Liu NS; Yang Y; Hess M; Walker PL; Smith TL; Dang NH Cancer; 2005 May; 103(10):2091-8. PubMed ID: 15816054 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]